^
Association details:
Biomarker:MTAP deletion
Cancer:Solid Tumor
Drug:TNG908 (PRMT5 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Excerpt:
...Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

3941 / 15 - TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies

Published date:
03/09/2022
Excerpt:
In summary, TNG908 is a novel, potent PRMT5 inhibitor with excellent drug-like properties and strong preclinical activity in multiple xenograft models that has the potential for histology-agnostic clinical development in MTAP-deleted solid tumors.